全文获取类型
收费全文 | 68257篇 |
免费 | 4855篇 |
国内免费 | 2469篇 |
专业分类
耳鼻咽喉 | 307篇 |
儿科学 | 943篇 |
妇产科学 | 1000篇 |
基础医学 | 11753篇 |
口腔科学 | 949篇 |
临床医学 | 3709篇 |
内科学 | 10667篇 |
皮肤病学 | 1045篇 |
神经病学 | 10296篇 |
特种医学 | 819篇 |
外国民族医学 | 19篇 |
外科学 | 4086篇 |
综合类 | 7372篇 |
现状与发展 | 7篇 |
预防医学 | 1598篇 |
眼科学 | 608篇 |
药学 | 12926篇 |
5篇 | |
中国医学 | 1424篇 |
肿瘤学 | 6048篇 |
出版年
2024年 | 91篇 |
2023年 | 756篇 |
2022年 | 1321篇 |
2021年 | 2009篇 |
2020年 | 1736篇 |
2019年 | 1775篇 |
2018年 | 1856篇 |
2017年 | 1869篇 |
2016年 | 1942篇 |
2015年 | 2282篇 |
2014年 | 3739篇 |
2013年 | 4989篇 |
2012年 | 3713篇 |
2011年 | 4325篇 |
2010年 | 3582篇 |
2009年 | 3680篇 |
2008年 | 3991篇 |
2007年 | 3603篇 |
2006年 | 3131篇 |
2005年 | 2689篇 |
2004年 | 2539篇 |
2003年 | 2344篇 |
2002年 | 1877篇 |
2001年 | 1631篇 |
2000年 | 1483篇 |
1999年 | 1305篇 |
1998年 | 1486篇 |
1997年 | 1378篇 |
1996年 | 1257篇 |
1995年 | 985篇 |
1994年 | 911篇 |
1993年 | 819篇 |
1992年 | 611篇 |
1991年 | 565篇 |
1990年 | 419篇 |
1989年 | 358篇 |
1988年 | 308篇 |
1987年 | 283篇 |
1986年 | 293篇 |
1985年 | 344篇 |
1984年 | 281篇 |
1983年 | 175篇 |
1982年 | 232篇 |
1981年 | 187篇 |
1980年 | 134篇 |
1979年 | 84篇 |
1978年 | 56篇 |
1977年 | 42篇 |
1976年 | 35篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 343 毫秒
51.
P. A. Milligan P. E. McGill C. W. Howden A. W. Kelman B. Whiting 《European journal of clinical pharmacology》1993,45(6):507-512
Summary A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine.Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L–1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period).A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation.No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations. 相似文献
52.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
53.
《中国药理学与毒理学杂志》1997,(1)
本实验探讨了内源性速激肽是否参与白三烯C4(LTC4)的气道效应.LTC4(0.5μgkg-1,iv)可增高豚鼠肺内压(IPP)和气道内依文思蓝渗出。速激肽NK-1受体拮抗剂CP-96345{(2S,3S)-顺式-2-(二苯甲基)-N-[(2-甲氧苯)-甲基]-1-杂氮双环[2.2.2]辛烷-3-胺}1mgkg-1,iv,可减弱LTC4诱导的依文思蓝渗出;NK-2受体拮抗剂SR-48968{(S)-N-甲基-N-[4-(4-乙酰氨基-4-苯基哌啶)-2-(3,4-二氯苯基)丁基]苯甲酰胺},1mgkg-1,iv,可抑制IPP的增高.白三烯拮抗剂ONO-1078(0.03mgkg-1,iv)可阻断这两种反应.结果说明内源性速激肽增强LTC4的气道作用,其中NK-1受体介导微血管渗漏,NK-2受体介导支气管收缩. 相似文献
54.
Serotonin (5-HT) is a mediator (through 5-HT1P receptors) of slow EPSPs in myenteric ganglia of the small intestine. The effect of 5-HT can be mimicked by elevating cAMP; therefore, we tested the hypothesis that the slow EPSP-like response to 5-HT is cAMP-mediated. Guinea pig gut was enzymatically dissociated; myenteric ganglia remained intact and were collected by filtration. Neurons in the isolated ganglia retained their ability to manifest the slow EPSP-like response to 5-HT. Exposure to 5-HT raised the ganglionic level of cAMP (ED50 0.3 μM). This effect was not antagonized by the 5-HT1P antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (100.0 μM), or mimicked by the 5-HT1P agonist, 5-hydroxyindalpine (10.0 μM). Increases in cAMP were also evoked by the 5-HT1 agonist, 5-carboxyamidotryptamine (10.0 μM), the 5-HT2 agonist, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 1.0–10.0 μM), and by the 5-HT4 agonists, renzapride (1.0–10.0 μM) and 5-methoxytryptamine (1.0–10.0 μM); however, neither the 5-HT1/5-HT2 antagonists, spiperone, methysergide, and methiothepin, nor the 5-HT4 antagonist, tropisetron (ICS 205–930; 10.0 μM), were able to inhibit the rise in cAMP evoked by these compounds or by 5-HT (0.1–10.0 μM). The 5-HT-evoked elevation of cAMP was antagonized by ketanserin (10.0 μM), which also blocked the effects of 5-methoxytryptamine and DOI, but not those of renzapride. The effective concentration of DOI, however, was higher than that needed for activation of 5-HT2 receptors, and Northern analysis using a cDNA probe encoding the rat 5-HT2 receptor failed to reveal the presence of 5-HT2 mRNA in myenteric ganglia, although it hybridizes with mRNA of the right size in the guinea pig brain. Compounds that failed to change levels of cAMP or to antagonize the action of 5-HT included 8-hydroxy-di-n-propylamino tetralin, R58639, R88226, and sumatriptan. It is concluded that the receptor responsible for the 5-HT-induced rise in cAMP in ganglia isolated from the guinea pig myenteric plexus is not a known subtype of 5-HT receptor. Since the pharmacology of this novel receptor is different from that of the slow EPSP-like response to 5-HT, the receptor probably does not mediate the slow EPSP. © 1993 Wiley-Liss, Inc. 相似文献
55.
目的研究不同剂量60Co γ射线辐照全血在保存期内红细胞CR1分子数目的变化.方法应用酶联法定量测定经15~35GY五个照射剂量辐照全血在保存期内红细胞CR1分子数目.结果照射后1d,15~25GY剂量组红细胞CR1分子数目相互间比较及分别与对照组比较无明显差异(P>0.05);经30、35GY辐照红细胞CR1分子数目分别与其他剂量组和对照组比较有明显差异(P<0.05~0.01).另外,随着保存期的延长,各剂量组和对照组红细胞CR1分子数目呈阶梯式下降,尤其在照射后3d,30和35GY剂量组红细胞CR1分子数目接近于照射后7d水平,二者相互比较无明显差异(P>0.05).结论在一定范围内(15~25GY)60Co γ射线剂量辐照对红细胞CR1分子数目无明显影响. 相似文献
56.
Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. 总被引:13,自引:0,他引:13
Elliott J Mufson Shuang Y Ma John Dills Elizabeth J Cochran Sue Leurgans Joanne Wuu David A Bennett Syed Jaffar Michelle L Gilmor Alan I Levey Jeffrey H Kordower 《The Journal of comparative neurology》2002,443(2):136-153
The long-held belief that degeneration of the cholinergic basal forebrain was central to Alzheimer's disease (AD) pathogenesis and occurred early in the disease process has been questioned recently. In this regard, changes in some cholinergic basal forebrain (CBF) markers (e.g. the high affinity trkA receptor) but not others (e.g., cortical choline acetyltransferase [ChAT] activity, the number of ChAT and vesicular acetylcholine transporter-immunoreactive neurons) suggest specific phenotypic changes, but not frank neuronal degeneration, early in the disease process. The present study examined the expression of the low affinity p75 neurotrophin receptor (p75(NTR)), an excellent marker of CBF neurons, in postmortem tissue derived from clinically well-characterized individuals who have been classified as having no cognitive impairment (NCI), mild cognitive impairment (MCI), and mild AD. Relative to NCI individuals, a significant and similar reduction in the number of nucleus basalis p75(NTR)-immunoreactive neurons was seen in individuals with MCI (38%) and mild AD (43%). The number of p75(NTR)-immunoreactive nucleus basalis neurons was significantly correlated with performance on the Mini-Mental State Exam, a Global Cognitive Test score, as well as some individual tests of working memory and attention. These data, together with previous reports, support the concept that phenotypic changes, but not frank neuronal degeneration, occur early in cognitive decline. Although there was no difference in p75(NTR) CBF cell reduction between MCI and AD, it remains to be determined whether these findings lend support to the hypothesis that MCI is a prodromal stage of AD. 相似文献
57.
58.
59.
目的 :探讨血清可溶性白细胞介素 2受体 (sIL 2R)在慢性乙型病毒性肝炎 (慢乙肝 )中的发病机制及sIL 2R与肝纤维化指标、肝功能的相关关系。方法 :对 312例肝活检病人按组织病理学炎症和纤维化程度进行分级分期 ,同时检测了病人血清sIL 2R、肝功能及肝纤维化相关指标。结果 :血清sIL 2R均值较对照组明显增高 (P <0 .0 1) ,增幅随着肝脏病理炎症和纤维化程度的加重而逐渐加大 ,各组间比较差异有显著性 (P <0 .0 5或P <0 .0 1)。sIL 2R与血清白蛋白 (A)呈显著负相关 ,与血清脯氨酸肽酶 (PLD)、Ⅳ型胶原 (CⅣ )、层粘连蛋白 (LN)、透明质酸 (HA)、Ⅲ型前胶原氨基端肽 (PⅢNP)、肝功指标中的TB、DB、G、ALT、AST、AKP、γ GT呈显著正相关 (P <0 .0 5或P <0 .0 1)。结论 :慢乙肝病人血清sIL 2R水平与A呈显著负相关 ,与PLD、CⅣ、LN、HA、PⅢNP呈显著正相关 ;sIL 2R的血清水平能反映肝脏组织学病变的程度 ,可作为判断肝组织炎症和纤维化程度的参考指标。 相似文献
60.
慢传输性便秘结肠阿片受体的病理生理改变 总被引:9,自引:0,他引:9
目的探讨慢传输性便秘(STC)的发病机制和病理生理改变。方法应用放射配体结合分析法,检测患者结肠mu、kappa阿片受体,观察其含量变化。结果STC患者结肠mu阿片受体的最大结合数(Bmax)和解离常数(KD)比正常对照组明显增加(Bmax400.950比96.304pmol,KD431.314比179.839pmol);kappa阿片受体含量检测亦有类似结果(Bmax:375.073比45.264pmol,KD485.407比141.016pmol)。结论STC患者阿片受体含量增加,内源性阿片肽活性增加。提示采用阿片受体拮抗剂可能是治疗STC的一个新途径。 相似文献